News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,935 Results
Type
Article (14278)
Company Profile (281)
Press Release (254376)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79545)
Career Advice (153)
Deals (13232)
Drug Delivery (35)
Drug Development (50471)
Employer Resources (31)
FDA (5728)
Job Trends (5139)
News (144461)
Policy (10034)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21681)
ALS (69)
Alzheimer's disease (851)
Antibody-drug conjugate (ADC) (108)
Approvals (5754)
Artificial intelligence (134)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (161)
Cancer (1525)
Cardiovascular disease (121)
Career advice (134)
Career pathing (2)
CAR-T (124)
Cell therapy (343)
Cervical cancer (9)
Clinical research (41178)
Collaboration (560)
Compensation (281)
Complete response letters (13)
COVID-19 (1034)
CRISPR (44)
C-suite (172)
Cystic fibrosis (78)
Data (1619)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1303)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (92)
Earnings (30134)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48804)
Executive appointments (476)
FDA (6501)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (517)
Gene editing (102)
Generative AI (10)
Gene therapy (266)
GLP-1 (372)
Government (1084)
Grass and pollen (2)
Guidances (70)
Healthcare (6595)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (100)
Indications (20)
Infectious disease (1101)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7282)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (215)
Leadership (3)
Legal (1386)
Liver cancer (34)
Lung cancer (207)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (148)
MASH (63)
Medical device (2603)
Medtech (2604)
Mergers & acquisitions (6291)
Metabolic disorders (407)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (73)
Neuropsychiatric disorders (25)
Neuroscience (1278)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (22)
Obesity (197)
Opinion (103)
Ovarian cancer (67)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (124)
Partnered (8)
Patents (137)
Patient recruitment (83)
Peanut (35)
People (25685)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14549)
Phase II (19161)
Phase III (12100)
Pipeline (947)
Policy (49)
Postmarket research (852)
Preclinical (6163)
Press Release (30)
Prostate cancer (64)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (299)
Real estate (1419)
Recruiting (12)
Regulatory (8678)
Reports (17)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (5)
RNA editing (5)
RSV (10)
Schizophrenia (64)
Series A (100)
Series B (70)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1977)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (217)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (79)
Last 7 days (623)
Last 30 days (1890)
Last 365 days (19338)
2025 (7113)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17354)
Australia (2944)
California (4079)
Canada (1177)
China (378)
Colorado (153)
Connecticut (156)
Delaware (110)
Europe (37350)
Florida (498)
Georgia (124)
Idaho (16)
Illinois (240)
India (10)
Indiana (94)
Iowa (2)
Japan (80)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (494)
Massachusetts (3254)
Michigan (74)
Minnesota (152)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1012)
New Mexico (12)
New York (1091)
North Carolina (572)
North Dakota (5)
Northern California (1822)
Ohio (115)
Oklahoma (9)
Oregon (21)
Pennsylvania (771)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1564)
Tennessee (25)
Texas (474)
United States (13934)
Utah (56)
Virginia (84)
Washington D.C. (31)
Washington State (362)
Wisconsin (17)
268,935 Results for "iteos therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
April 29, 2025
·
11 min read
Cancer
Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data
Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos will deprioritize the development of inupadenant after it failed to meet the biotech’s clinical bar in a Phase II study of metastatic non-small cell lung cancer.
December 13, 2024
·
2 min read
·
Tristan Manalac
Genetown
iTeos Therapeutics Announces $120 Million Registered Direct Offering
iTeos Therapeutics, Inc. announced that it has entered into a securities purchase agreement to sell 1,142,857 shares of the Company’s common stock at a price of $17.50 per share, representing a premium of approximately 44% to iTeos’ closing price on May 9, 2024 and pre-funded warrants to purchase up to 5,714,285 shares of the Common Stock at a price of $17.499 per pre-funded warrant, in a registered direct offering.
May 10, 2024
·
6 min read
Press Releases
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 5, 2025
·
11 min read
Press Releases
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
January 13, 2025
·
9 min read
Lung cancer
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light for anti-TIGIT therapies after a string of failures.
September 16, 2024
·
2 min read
·
Tristan Manalac
Press Releases
iTeos to Participate in Upcoming Investor Conferences
November 26, 2024
·
1 min read
Press Releases
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
1 min read
Press Releases
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
March 25, 2025
·
4 min read
Business
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
May 10, 2024
·
11 min read
1 of 26,894
Next
